Eli Lilly and Co (HAM:LLY) Cyclically Adjusted PB Ratio: (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:LLY Eli Lilly and Co HAM:LLY
92 GF Score
Price €1,020.20
GF Value €1,244.96
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Eli Lilly and Co Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Eli Lilly and Co  (HAM:LLY) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Eli Lilly and Co Cyclically Adjusted PB Ratio Related Terms


Eli Lilly and Co Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Eli Lilly and Co's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co Cyclically Adjusted PB Ratio Chart

Eli Lilly and Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.03 28.80 46.93 63.07 82.04

Eli Lilly and Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 62.08 59.43 82.04 66.90 83.32

HAM:LLY vs JNJ, ABBV, MRK: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Cyclically Adjusted PB Ratio falls into.


HAM:LLY
92GF Score
Eli Lilly and Co HAM:LLY
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eli Lilly and Co Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Eli Lilly and Co's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Eli Lilly and Co's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=32.905/333.9520*333.9520
=32.905

Current CPI (Jun. 2026) = 333.9520.

Eli Lilly and Co Quarterly Data

Book Value per Share CPI Adj_Book
201609 12.582 241.428 17.404
201612 12.062 241.432 16.684
201703 11.890 243.801 16.287
201706 11.399 244.955 15.540
201709 11.346 246.819 15.351
201712 8.905 246.524 12.063
201803 10.782 249.554 14.428
201806 9.210 251.989 12.206
201809 10.499 252.439 13.889
201812 8.173 251.233 10.864
201903 2.261 254.202 2.970
201906 2.547 256.143 3.321
201909 3.199 256.759 4.161
201912 2.450 256.974 3.184
202003 2.912 258.115 3.768
202006 3.800 257.797 4.923
202009 4.284 260.280 5.497
202012 4.848 260.474 6.216
202103 6.040 264.877 7.615
202106 5.592 271.696 6.873
202109 6.893 274.310 8.392
202112 8.333 278.802 9.981
202203 8.913 287.504 10.353
202206 8.507 296.311 9.588
202209 10.704 296.808 12.044
202212 10.581 296.797 11.906
202303 11.010 301.836 12.181
202306 10.757 305.109 11.774
202309 11.075 307.789 12.016
202312 10.983 306.746 11.957
202403 13.091 312.332 13.997
202406 13.993 314.175 14.874
202409 14.258 315.301 15.101
202412 15.186 315.605 16.069
202503 16.244 319.799 16.963
202506 17.665 322.561 18.289
202509 22.629 324.800 23.267
202512 25.325 324.054 26.099
202603 30.203 330.213 30.545
202606 32.905 333.952 32.905

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Eli Lilly and Co (HAM:LLY) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of €1,020.20 is trading 18.1% below its estimated GF Value™ of €1,244.96. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for HAM:LLY:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €1,244.96 vs. price of €1,020.20 (18.1% below fair value)
  • GF Score™: 92/100 with 4 warning signs

No single metric tells the full story. See the HAM:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
92GF Score

Get the complete analysis for HAM:LLY

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1,020.20
Price
€1,244.96
GF Value